

February 27, 2024

Delivered by email: [memlys@gmail.com](mailto:memlys@gmail.com)

**Re: ISCT 2024 Early Stage Professionals Award**

Dear Memnon Lysandrou,

Thank you for submitting your abstract “*FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION*” to the ISCT 2024 Vancouver Annual Meeting. ISCT received a very large number of abstract submissions this year and we are pleased to inform you that you have been selected to receive the \$1000 USD **Early Stage Professionals Award**, sponsored by ISCT. Congratulations on this remarkable achievement!

In order to ensure receipt of this notification, please kindly send acknowledgment by reply email and confirm your acceptance of the award to Vanessa Ho ([vanessaho@isctglobal.org](mailto:vanessaho@isctglobal.org)).

Please note that in order to be eligible for the award, you must present your abstract at the ISCT 2024 Vancouver Annual Meeting and hold a current ISCT membership (<https://isctglobal.org/page/IndividualMembership>).

Once you have accepted your award, ISCT will contact you to coordinate the delivery of the plaque and monetary award.

Thank you for choosing the ISCT 2024 Vancouver Annual Meeting for submission of your work, and please let us know if you have any questions about your **ISCT 2024 Early Stage Professionals Award**. Congratulations once again on the selection of your abstract for this Award.

We look forward to seeing you at the ISCT 2024 Vancouver Annual Meeting.


Sincerely,



**Daniel J. Weiss, MD, PhD**  
University of Vermont  
Burlington, VT, United States



**Sowmya Viswanathan, PhD**  
University Health Network  
Toronto, ON, Canada



**Aby J. Mathew, PhD**  
BioLife Solutions  
Bothell, WA, United States